tiprankstipranks

Jane Huang Insider Profile

4 Followers
Jane Huang, CMO, Hematology at BeiGene, holds 160.06K shares in BeiGene (Ticker: BGNE), holds ― shares in Protara Therapeutics (Ticker: TARA), holds 63.34K shares in Prelude Therapeutics (Ticker: PRLD).
tipranks
Jane Huang

Jane Huang
BeiGene (BGNE)
CMO, Hematology

Ranked #30,156 out of 99,335 Corporate Insiders

Profitable Transactions

57%
4 out of 7 Profitable Transactions

Average Return

+4.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$30M
99.80%
0.20%
0.00%
A breakdown of Jane Huang's holdings

Insider Roles

BeiGene
(BGNE)
CMO, Hematology
Prelude Therapeutics
(PRLD)
President, CMO
Protara Therapeutics
(TARA)
Director
Roles that Jane Huang holds in companies

Most Profitable Insider Trade

Stock:
BeiGene
(BGNE)
Rating:Informative Sell
Date:Jun 09, 2021 - Jun 09, 2022
Return:+56.60%
The most profitable trade made by Jane Huang

Jane Huang's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
BeiGene
Dec 16, 2021
CMO, Hematology
Uninformative Buy
179.94K
$30.05M
Protara Therapeutics
Director
Prelude Therapeutics
Oct 07, 2024
President, CMO
Uninformative Buy
12.05K
$60.81K
List of latest transactions for each holding click on a transaction to see Jane Huang's performance on stock

Jane Huang insider profile FAQ

What is the percentage of profitable transactions made by Jane Huang?
The percentage of profitable transactions made by Jane Huang is 57%.
    What is the average return per transaction made by Jane Huang?
    The average return per transaction made by Jane Huang is 4.10%.
      What stocks does Jane Huang hold?
      Jane Huang holds: BGNE, TARA, PRLD stocks.
        What was Jane Huang’s latest transaction?
        Jane Huang latest transaction was an Uninformative Buy of $179.94K.
          What was Jane Huang's most profitable transaction?
          Jane Huang’s most profitable transaction was an Informative Sell of BGNE stock on June 9, 2021. The return on the trade was 56.60%.
            What is Jane Huang's role in BeiGene?
            Jane Huang's role in BeiGene is CMO, Hematology.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.